Site Editor

Thomas Flaig, MD

Advertisement

Advertisement

JNCCN Spotlights

Enfortumab Vedotin-ejfv (Padcev)

Medical Literature

Immunotherapy for Urothelial Cancer: Balancing Benefits and Risks

News

Durvalumab Indication Withdrawn in Advanced Bladder Cancer in the United States

News

Are There Racial Disparities in BCG Treatment of Non–Muscle Invasive Bladder Cancer?

News

GU Symposium 2021: Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Cancer

Medical Literature

Measures of Tumor Heterogeneity: Useful Biomarkers of Bladder Carcinoma?

JNCCN Spotlights

Enfortumab Vedotin-ejfv (Padcev)

Syed A. Hussain, MD, on Neoadjuvant Treatment With Nintedanib for Locally Advanced Disease

Monika Joshi, MD, on After the DUART Trial: Next Steps in Treating Urothelial Cancer of the Bladder

View More

Advertisement

JNCCN Spotlights

Enfortumab Vedotin-ejfv (Padcev)

View More

More

News

Are There Racial Disparities in BCG Treatment of Non–Muscle Invasive Bladder Cancer?

Avelumab Plus Axitinib Under Study in Urothelial Cancer

Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma

FDA Brief: Novel Treatment of Upper Tract Urothelial Cancer Granted Fast Track Designation

GU Symposium 2021: Impact of Gender on Surgical Outcomes After Radical Cystectomy

Are High 12-Chemokine Scores Prognostic in Muscle-Invasive Bladder Cancer?

JAVELIN Bladder 100: Avelumab Maintenance for Advanced Urothelial Carcinoma

Are There Racial Disparities in Mortality in Muscle-Invasive Bladder Cancer?

View More

Advertisement

Published

Medical Literature

Combination Regimen Under Study in Metastatic Urothelial Carcinoma

Update on Managing Non–Muscle-Invasive Bladder Cancer

Can Leukocyte Telomere Length Predict Bladder Cancer Risk?

Bladder Urothelial Carcinoma: Is Age Related to Risk of Lymph Node Metastasis?

View More

Ongoing

CE Activities

New Therapeutic Developments In Urothelial Cancer: Clinical Trial Evidence And Expert Guidance

Advances in Treatment of Urothelial Carcinoma

Metastatic Urothelial Carcinoma: 2020 Multidisciplinary Molecular Tumor Board

Current and Emerging Treatment Options for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Carcinoma)

View More

Available

Clinical Trials

Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

View More

Resources

For Your Patients

Bladder Cancer Advocacy Network

American Cancer Society

American Bladder Cancer Society

JNCCN: How To Manage Cancer Care During COVID-19 Pandemic

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.